Crescent Biopharma (CBIO) investor relations material

Strategic vision and clinical development

• Pursuing a two-pronged approach with a next-gen IO bispecific (CR-001) and an ADC portfolio, aiming for leadership in oncology.

• Initiated clinical dosing for CR-001 and CR-003 in early 2024, with three INDs cleared and four clinical studies planned this year.

• Expecting robust clinical data readouts for CR-001 and CR-003 starting in Q1 2027, guiding future development and indication prioritization.

Data strategy and indication selection

• Focusing on three data buckets by mid-2027: frontline non-small cell lung cancer, CR-001 combinations with chemo, and ADC combos.

• Indication prioritization will be data-driven, targeting areas for first-in-class or best-in-class opportunities.

• Global phase I/II ASCEND trial covers eight indications, with iterative dose escalation and tumor-specific backfill cohorts.

Global trial design and data translatability

• Running global trials in the US, Europe, and Asia-Pacific, with parallel studies in China via Kelun-Biotech partnership.

• Confident in data translatability between Asian and Western populations, supported by meta-analyses and ongoing global studies.

• Anticipating that PD-1 x VEGF bispecifics could become the next-generation IO backbone, potentially replacing PD-1 inhibitors.